Cargando…
Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration
Inhibition of vascular endothelial growth factor, a key contributor to the choroidal neovascularization associated with wet age-related macular degeneration, is the mode of action of several approved therapies, including aflibercept, which requires frequent intravitreal injections to provide clinica...
Autores principales: | Grishanin, Ruslan, Vuillemenot, Brian, Sharma, Pallavi, Keravala, Annahita, Greengard, Judith, Gelfman, Claire, Blumenkrantz, Mark, Lawrence, Matthew, Hu, Wenzheng, Kiss, Szilárd, Gasmi, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319194/ https://www.ncbi.nlm.nih.gov/pubmed/30528929 http://dx.doi.org/10.1016/j.ymthe.2018.11.003 |
Ejemplares similares
-
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021) -
Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020) -
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates
por: Kiss, Szilárd, et al.
Publicado: (2021) -
Imaging of Wet Age-Related Macular Degeneration
por: Kenan, Damer
Publicado: (2016) -
Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for the Treatment of Wet Age-Related Macular Degeneration
por: Maharjan, Pooja, et al.
Publicado: (2019)